贝达药业(300558) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥569,266,996.07, representing a 2.42% increase year-over-year, while the year-to-date revenue reached ¥1,724,419,673.98, up 14.37% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2021 was ¥131,770,354.58, a decrease of 64.39% year-over-year, with a year-to-date net profit of ¥346,853,778.64, down 32.50% compared to the previous year[5] - The company reported a basic earnings per share of ¥0.32 for Q3 2021, down 65.22% year-over-year, and a diluted earnings per share of ¥0.31, down 65.93%[5] - Total operating revenue for the third quarter reached CNY 1,724,419,673.98, an increase of 14.4% compared to CNY 1,507,722,516.09 in the same period last year[27] - Net profit attributable to the parent company was CNY 346,853,778.64, down 32.5% from CNY 513,827,655.16 in the previous year[28] - Operating profit decreased to CNY 383,479,137.34, a decline of 37.4% compared to CNY 613,155,872.02 in the same quarter last year[27] - Total comprehensive income for the period was CNY 419,244,792.19, compared to CNY 504,864,053.52 in the same quarter last year[28] - Basic earnings per share decreased to CNY 0.84 from CNY 1.28 in the previous year[28] Research and Development - Research and development expenses for the first nine months of 2021 totaled ¥60,217,570, accounting for 34.92% of total revenue, reflecting a 37.02% increase year-over-year[7] - Research and development expenses increased to CNY 365,531,682.04, representing a 37.0% rise from CNY 266,779,354.07 in the prior year[27] - The company has received clinical trial approval for BPI-23314 tablets, indicating ongoing investment in new product development[25] Cash Flow and Assets - The company's cash flow from operating activities for the year-to-date period was ¥460,457,758.90, showing a decrease of 6.09% compared to the previous year[5] - Cash flow from operating activities generated CNY 460,457,758.90, slightly down from CNY 490,329,482.04 in the previous year[30] - Total assets at the end of Q3 2021 were ¥5,681,035,768.82, an increase of 8.63% from the end of the previous year[5] - The company's cash and cash equivalents decreased by 44.23% to ¥750,593,035.82 compared to the end of the previous year[8] - The company's cash and cash equivalents decreased to CNY 750,593,035.82 from CNY 1,345,944,580.99, a decline of about 44.2%[24] - Accounts receivable increased by 163.20% to ¥138,476,016.95, attributed to increased sales of new drugs[8] - Inventory levels rose to CNY 279,213,920.81, up from CNY 188,593,932.18, indicating an increase of around 48.0%[24] - Total liabilities reached CNY 1,158,889,108.06, compared to CNY 1,085,342,634.36 at the end of 2020, reflecting an increase of about 6.8%[26] - The company's equity attributable to shareholders increased to CNY 4,522,508,063.49 from CNY 4,140,781,110.43, representing a growth of approximately 9.2%[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,100, with the top 10 shareholders holding a combined 66.54% of shares[10] - Ningbo Kaiming Investment Management Partnership holds 19.28% of shares, amounting to 80,064,000 shares, and has pledged 37,810,000 shares[10] - Zhejiang Jihe Venture Capital holds 13.08% of shares, totaling 54,324,000 shares[10] - The total number of shares held by the top 10 shareholders is 277,000,000 shares[11] - The actual controller holds a total of 23.02% of shares through various investment partnerships[11] - The number of shares held by the top 10 shareholders participating in margin trading is 77,284,000 shares[11] Stock Options and Incentives - The company has implemented stock option incentive plans, with 231 participants exercising options at a price of 34.85 RMB per share, involving 2,142,190 options[15] - The total share capital increased from 41,498,520 shares to 41,530,510 shares due to the exercise of stock options[15] - The company has a total of 1,416,665 restricted shares at the end of the reporting period, with 12,750 shares released from restrictions[13] - The total number of restricted shares to be granted under the 2021 incentive plan has been adjusted from 15.55 million shares to 15.53 million shares, with the number of incentive recipients reduced from 468 to 466[19] - The initial grant of restricted shares has been adjusted from 12.7479 million shares to 12.7279 million shares, with a reserved portion of 2.8021 million shares, accounting for 18.04% of the total[19] - The cumulative number of stock options exercised and registered as of the report date is 2.14219 million shares, representing 96.25% of the total available options[16] Other Financial Information - The company reported a significant increase in other receivables by 472.12% to ¥38,955,380.86, mainly due to increased employee stock option tax receivables[8] - The company reported a net cash outflow from investing activities of CNY -899,198,899.41, compared to CNY -446,143,499.85 in the previous year[30] - The company’s financial statements for the third quarter of 2021 were unaudited[36]